Decnupaz Injection, Powder, Lyophilized, For Solution
Product Images NDC 0074-0282

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Decnupaz (NDC 0074-0282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pivekimab Sunirine-pvzy Has The Following Structure: (Pivekimab Sunirine Pvek 01)

Chemical structure diagram of pivekimab sunirine-pvzy showing the molecular linkage between the drug moiety and an antibody labeled as G4723A. The structure illustrates the complex conjugation typical of antibody-drug conjugates.*

FDA Label Image

Principal Display Panelndc 0074-0282-02decnupaztm Pivekimab Sunirine-pvzyfor Injection2 mg Per Vialwarning: Hazardous Drugfor Intravenous Infusion Afterreconstitution And Two Dilutions1 Single-dose Vialdiscard Unused Portiondispense The Enclosed Medicationguide To Each Patientrx Onlyabbvie (Pivekimab Sunirine Pvek 02)

Packaging label for DECNUPAZ 2 mg per vial, a lyophilized powder injection of pivekimab sunirine-pvzy for intravenous use. The label indicates single-dose vial usage with warnings for hazardous drug handling, storage instructions, and reconstitution directions. The labeler is AbbVie Inc., and the NDC is 0074-0282.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.